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Abstract
Background: Sensory disturbances in fibromyalgia extend beyond nociception. It has been proposed that
imbalance in the mutual competition between painful input and non-painful sensory activity may, to a significant
extent, account for the augmented subjective perception of pain. In this context, non-nociceptive somatosensory
stimulation could arguably attenuate fibromyalgia symptoms by restoring the sensory balance. We specifically
tested the effect of vibrotactile stimulation on symptom relief in fibromyalgia patients with a randomized, double-
blind, sham-controlled, crossover clinical trial.
Methods: Seventy-seven female patients were randomized and data from 63 valid cases were analyzed. Active
intervention involved extensive body stimulation with gentle mechanical vibrations administered during 3 h at
night for 3 weeks, and the placebo effect was controlled using identical instruments to simulate an alternative
treatment option. The primary outcome measure combined pain, fatigue, and complaints of poor cognition.
Results: Vibrotactile stimulation was significantly superior to sham in alleviating fibromyalgia symptoms globally.
However, univariate analyses showed that the effect was not universal. Benefits were perceived on unpleasant
somatic sensations such as generalized pain and fatigue, but not on poor cognition, anxiety, and depression.
Vibrotactile stimulation was notably well tolerated and sleep quality significantly improved despite the fact that
vibrations were administered at night.
Conclusions: Results thus provide new evidence that non-nociceptive somatosensory stimulation may favorably act
upon altered somatosensory balance in fibromyalgia. From a clinical perspective, both the degree of improvement
and the easy application of our proposal would seem to support a potential role for vibrotactile stimulation in the
symptomatic treatment of fibromyalgia.
Trial registration: ClinicalTrials.gov registration number NCT03227952. Registered 24 July, 2017.
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Background
Fibromyalgia has been a controversial disorder in some
medical contexts due to the subjective nature of its
symptoms. Patients indeed complain of generalized pain,
fatigue, unrefreshing sleep, and poor cognition in the
absence of an observable organic cause [1]. Nevertheless,
current methods for studying neural function offer new
opportunities to explore subtle clinical phenomena. One
such tool that contributes to characterizing the patho-
physiology of fibromyalgia is functional MRI [2–4]. By
means of functional connectivity and task activation ap-
proaches, we have recently observed functional alter-
ations beyond the nociceptive domain which would
suggest a weak integration of other sensory inputs con-
tributing to clinical pain in fibromyalgia [5, 6]. Other re-
search has provided data consistent with such a
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downregulation of the non-nociceptive component of
somatosensory processing [7–12].
It has been proposed that imbalance in the mutual com-
petition between painful inputs and non-painful sensory ac-
tivity may, to a significant extent, account for the
augmented subjective perception of pain and body discom-
fort [6]. In this context, non-nociceptive somatosensory
stimulation could arguably attenuate fibromyalgia symp-
toms by restoring the sensory balance, regardless of
whether non-painful sensory activity alteration is a primary
phenomenon or a by-product of originally facilitated (or de-
ficiently filtered) nociceptive signals. There are empirical
studies demonstrating the beneficial effects of treatments
based on physical/sensory stimulation that do not directly
aim at the nociceptive system. Tested procedures showing
a range of success include, for instance, physical exercise
and movement-based therapies, hydrotherapy, and periph-
eral nerve stimulation [11, 13–17]. Interestingly, the bene-
fits of non-nociceptive stimulation contrast with the
paradoxically poor efficacy of genuine analgesic drugs in re-
lieving fibromyalgia pain [13, 15, 18].
One way to selectively stimulate the non-nociceptive
component of the somatosensory system is by using
mechanical vibrations. Vibrotactile stimuli are captured
by a variety of widespread skin and musculoskeletal tis-
sue receptors and transmitted via large-diameter myelin-
ated fibers separately from the nociceptive pathway [19].
Experimental studies interestingly suggest that fibro-
myalgia pain can be effectively modulated by vibrotac-
tile stimuli [20]. Moreover, there are empirical studies
specifically testing the potential usefulness of vertical
oscillating platforms that have reported optimistic re-
sults [21–25]. However, there have been no previous
studies controlling for the possible placebo effects of
vibration-based treatments applied to fibromyalgia
patients.
In our study, we tested the effect of vibrotactile stimula-
tion on symptom relief in fibromyalgia patients with a ran-
domized, double-blind, sham-controlled, crossover clinical
trial. The intervention involved extensive body stimulation
with gentle mechanical vibrations administered during 3 h
at night for 3 weeks, and the placebo effect was controlled
using identical instruments to simulate an alternative
treatment option. The primary outcome was change in
the key symptoms of fibromyalgia combining pain, fatigue,
and complaints of poor cognition.
Materials and methods
This study was conducted in accordance with the princi-
ples expressed in the Declaration of Helsinki and was
approved by the Ethical Committee of Clinical Research
of the Parc de Salut Mar of Barcelona (reference no.
2016/6932/I). All patients provided written informed
consent. The trial was designed according to CONSORT
recommendations [26] and was registered at the US Na-
tional Institutes of Health (ClinicalTrials.gov), with iden-
tifier number NCT03227952 and title “Study of the
effectiveness of vibrotactile sensory stimulation in fibro-
myalgia patients”.
Participants
Patients were recruited from the Fibromyalgia Unit of
Barcelona’s Hospital del Mar - Parc de Salut Mar be-
tween September 2017 and May 2018. A total of 166 pa-
tients clinically diagnosed with fibromyalgia were
contacted through a consecutive order based on clinical
visit schedules (JB and JM). One hundred and seventeen
patients agreed to be screened for eligibility and were
fully briefed on the study and the corresponding inclu-
sion/exclusion criteria. Seventy-seven patients were
eventually randomized following the exclusion of 23 pa-
tients who did not meet study criteria and 17 patients
who declined to participate.
Eligibility criteria
Inclusion criteria were based on the following factors: fe-
male, aged 18 to 65 years, diagnosed by a specialist in
fibromyalgia in accordance with the American College
of Rheumatology classification and diagnostic criteria [1,
27], the patient did not suffer from any other disorder
that might account for the pain, chronic use treatments
in stable doses, a full understanding of the study, and an
express commitment to compliance. Criteria to exclude
patients were generalized inflammatory articular or
rheumatic disease; severe or non-stable medical, endo-
crine, or neurological disorder; psychotic disorder or
drug abuse; evidence of poor compliance; and events
that could relevantly interfere with the trial.
Intervention effects were evaluated when added to on-
going treatments. Changes in the previously prescribed
treatments and procedural therapies (e.g., nerve blocks
or joint injections) were forbidden throughout the trial.
Only variations in the daily dose of the habitual analge-
sics were allowed.
Study design
This randomized, double-blind, sham-controlled, two-
period crossover clinical trial measured the effect of
vibrotactile sensory stimulation versus sham treatment
on symptom relief in fibromyalgia patients. All patients
underwent a period of vibrotactile stimulation and a
period of sham with complete counterbalancing, half of
them in that sequence and the other half first receiving
sham treatment. Both treatments lasted 3 weeks and
were separated by a 2-week washout period.
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Study interventions
The active treatment involved whole-body sensory
stimulation with mechanical stimuli of vibrotactile (pal-
lesthetic) type at a relatively high rate, low intensity, and
long duration administered at sleep time. To generate
mechanical vibrotactile stimuli, 6 vibration motors (i.e.,
conventional electric motors with an eccentric mass
fixed to the rotor) were fitted into a standard mattress
(80 by 190 cm) symmetrically positioned to fully cover it,
with the exception of the area in which the patient’s
head lay while sleeping. The 6 vibration motors gener-
ated a slowly varying spectrum of frequencies ranging
from 2 to 90 Hz, which was mechanically transmitted to
the whole mattress. An electronic programmer was built
to control stimulus delivery for duration and intensity
(Fig. 1). The whole vibration system was manufactured
by LED SpA (Aprilia, Italy).
The treatment involved the application of vibrotactile
stimulation with a total daily duration of 3 h distributed
within a period of 2 h at bedtime and 1 h prior to getting
up. The intensity was set to 30% of power (see below) at
bedtime and 45% prior to getting up. Patients were
instructed to turn on the system at bedtime and try to
get to sleep naturally. The system was programmed to
automatically stop 2 h later. The following morning,
once the patients had naturally awoken, they were to set
the device to run for a further hour and remain in their
beds. Patients were allowed to fall asleep during this
period.
Intensity and frequencies of vibrations delivered were
measured in real conditions using a tri-axial accelerom-
eter specifically designed to measure the exposure of
workers to vibrations transmitted to the whole body
(CESVA AC033, CESVA Instruments, Barcelona) ac-
cording to the International Organization for Standardi-
zation’s norm ISO 2631-1. The accelerometer was
calibrated using the CESVA CV211 multi-frequency vi-
bration calibrator. Vibration spectrum was determined
using VSHOOTER VBS1T vibration analysis camera
(Synergys Technologies, Altkirch, France).
The measurements obtained indicated that the nor-
malized vibration intensity applied to the body at 30% of
Fig. 1 Instruments used to administer vibrotactile stimulation (above) and sham (bottom). An electronic engine controlled stimuli delivery.
Mechanical vibrotactile stimuli were generated using 6 vibration motors fitted into a standard mattress. Sham treatment was applied using
identical instruments, with an electrical signal turning on a pilot light to indicate that the (simulated) treatment was operative
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power in a 3-h exposure was 0.03 m/s2, and for 3 h at
45%, it was 0.04 m/s2. Such energy delivery is much
lower than the daily occupational exposure permitted
for whole-body vibrations at work (1.15 m/s2) according
to current European and Spanish regulations (Spanish
law RD 1311/2005). And also below the limit from
which adopting procedures for risk prevention at work
is recommended (0.5 m/s2). When the stimulus was set
at 30% of power, dominant frequencies were widely dis-
tributed with a peak at 22 Hz and secondary peaks from
4 to 90 Hz. When the stimulus was set at 45% of power,
the dominant frequency peaked at 30.6 Hz instead.
Sham treatment was applied using identical instru-
ments and with power and duration programmed identi-
cally. However, in this case, the output was not the
signal activating the vibration motors, but rather an elec-
trical signal turning on an incorporated pilot light indi-
cating that the (simulated) treatment was operating
(Fig. 1). The patient was told that “the study involved
the comparison of 2 treatment options; vibration versus
magnetic waves, both of which are potentially effective
treatments in fibromyalgia.” However, patients were
clearly informed that study interventions might or might
not be effective in the context of a clinical trial. The par-
ticipants were also informed that the interventions had no
known relevant health risks under the applied conditions.
Special attention was paid to ensuring blinding. One
blind researcher collected all outcome measures. Also,
the assessment interviews were entirely structured and
the interaction between the data collector and patients
was strictly limited to the questions of interest. No other
conversations were permitted during the interview. Prior
to the study, patients formally agreed not to interact
with the researcher collecting outcome measures. An-
other researcher was available throughout the study to
be consulted by patients in the event of doubt, adverse
effects, or any kind of incident. Assessment and moni-
toring were carried out in different centers with no
interaction during the evolution of the study.
Randomization
Patients were randomly assigned to the intervention se-
quence (vibrotactile stimulation first or sham first) with
an equal allocation ratio (1:1). The randomization scheme
was generated by means of the Web site Randomization.
com http://www.randomization.com. The system gener-
ated a unique number for each randomized patient. The
randomization schedule was stratified in blocks of 8. A
single independent researcher was aware of the
randomization process and randomization information
(LBH). This researcher was in charge of telephoning each
patient on the day to start the interventions to communi-
cate the device (real or sham) to be connected in each
phase.
Outcome measures
The primary outcome was “change in fibromyalgia’s key
symptoms rated by 101-point numerical rating scales
(NRS).” The effect on pain, fatigue, and “cognitive symp-
toms” was jointly analyzed using a repeated measures
multivariate analysis of variance (MANOVA) including
separate NRS scores. In addition, participants rated
intervention effects providing a single global NRS score
for all three symptoms (pain, fatigue, and cognitive
symptoms) considered together. This rating was given
by participants as a direct estimation of percentage (%)
improvement of their symptoms after the interventions.
The rationale for using such a combination of symp-
toms is their relevance in characterizing fibromyalgia as
a syndrome, in addition to “waking unrefreshed” [1].
“Waking unrefreshed” was not considered within the
primary outcome as the study’s intervention was applied
during the night and we had no a priori knowledge of its
effects on sleeping comfort.
Pain, fatigue, and cognitive symptoms were individu-
ally rated at study baseline as the overall symptom sever-
ity during the last month. Upon their first visit, patients
were specifically instructed and trained to rate symp-
toms using NRS, in which 0 was no symptoms and 100
the worst possible. Due to the large dispersion of spon-
taneous pain and subjective symptom measures in fibro-
myalgia patients [18, 28, 29], treatment effects on both
vibrotactile stimulation and sham were evaluated at the
end of the study using the initial scores as a reference.
To assist symptom rating, patients were instructed to
firstly evaluate the effects of the intervention as a per-
centage change (improvement or worsening). Percentage
ratings were then transformed into absolute NRS values.
Patients evaluated each treatment effect globally as sus-
tained (> 1 week) improvement (or worsening) attained
during each 3-week treatment period.
Secondary outcomes included the following: (i) “Unre-
freshed Sleep,” patients rated the quality of sleep by indi-
cating the severity (i.e., how much of a problem) of
awakening tired or unrefreshed using 101-point NRS. (ii)
“Daily Activity Impact,” the interference of fibromyalgia
in their daily life activities and quality was similarly
quantified using 101-point numerical ratings. (iii) “Emo-
tional Distress,” assessed on the Hospital Anxiety and
Depression Scale (HADS) [30, 31] with separate rating
for anxiety and depression. (iv) The Fibromyalgia Impact
Questionnaire (FIQ) [32], total score. Secondary out-
come measures were obtained both before and after
each treatment period.
Sample size
We estimated that a total of 58 valid patients would be
required to detect a difference between allocation groups
with a two-tailed α of 0.05, a “1-β” of 0.80, symptom
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reduction standard deviation of 20 points (on 101-point rat-
ings), and symptom reduction difference of 15 points (rele-
vant symptom reduction differences have been reported as
ranging from 10 to 20 in previous studies [33, 34]). If a po-
tential case loss of 20% is assumed, our aim was to
randomize a minimum of 73 patients (77 cases were finally
randomized).
Statistical analysis
The change regarding the corresponding baseline (pre
minus post) was used as a measure of treatment re-
sponse for pain, fatigue, and cognitive symptoms. Differ-
ences between sensory stimulation and sham effects
were jointly tested for all three key symptoms using re-
peated measures MANOVA. Within-subject effects were
then estimated with the repeated measures model for
each individual (pain, fatigue, and cognitive symptoms)
rating. To test intervention order effects, a between-
subject factor with two levels (sensory stimulation first or
sham first) was added to the repeated measures model.
Univariate analyses to compare intervention effects within
and between allocation groups were carried out using
paired t-test and two-sample t-test, respectively.
Secondary outcomes were analyzed similarly. Partici-
pants receiving at least 1 day of either study intervention
were included in adverse effect analyses. Proportions of
participants with adverse effects were analyzed using
Fisher’s exact test. All reported p values are two-tailed.
All analyses were conducted using SPSS software, ver-
sion 20.
Results
Of the 77 patients randomized, 10 patients discontinued
the study and 4 were excluded due to low treatment
Fig. 2 CONSORT flow diagram
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compliance. The final analyzed sample included 63 valid
patients, of whom 30 belonged to the “sham first” group
and 33 to the “vibrotactile stimulation first” group (Fig. 2)
. Baseline demographic and clinical characteristics are
detailed in Table 1.
Primary outcome
Repeated measures MANOVA including the variable
change (pre minus post) in NRS ratings for pain, fatigue,
and cognitive symptoms showed a significant within-
subject overall effect (vibrotactile stimulation versus
sham) with F = 4.0 and p = 0.012.
Significant differences between vibrotactile stimulation
and sham were also obtained for the percentage im-
provement rated for pain, fatigue, and cognitive symp-
toms globally. Changes in the global symptom score for
sham showed mean ± SD of 25.7% ± 30.7% and vibrotac-
tile stimulation 45.2% ± 33.9%, t = 3.4 and p = 0.001.
Fibromyalgia key symptoms
Univariate contrasts for the three fibromyalgia key symp-
toms showed score change indicating a symptom im-
provement significantly higher for vibrotactile stimulation
than for sham in pain and fatigue, but not in cognitive
symptoms (Table 2, Fig. 3).
Table 2 shows within and between comparisons for al-
location groups. A significant intervention order effect
was identified. That is, the difference between vibrotac-
tile stimulation and sham for pain and fatigue was sig-
nificantly greater in the “vibrotactile stimulation first”
group than in the “sham first” group (interaction “inter-
vention by order” showing F = 8.8 and p = 0.004 for pain,
and F = 10.7 and p = 0.002 for fatigue).
Figure 4 illustrates the intervention order effect for fa-
tigue ratings. There was a virtual absence of placebo ef-
fect in the sham condition when administered in the
second period (n = 33; mean ± SD pre minus post NRS,
3.5 ± 14.9; t = 1.3 and p = 0.190). Interestingly, the effect
of sham when administered first was similar to the effect
of vibrotactile stimulation when administered secondly
(n = 30; NRS 12.0 ± 18.4 versus 13.0 ± 18.0, t = − 0.2 and
p = 0.842). By contrast, the differences between both in-
terventions were notably large when vibrotactile stimula-
tion was administered first (n = 33; NRS 27.6 ± 24.1
versus 3.5 ± 14.9, t = 5.1 and p = 0.00001).
Another carryover phenomenon was that the effect of
vibrotactile stimulation, when administered first, did not
completely disappear at week 5 (i.e., 2 weeks after the
end of vibrotactile stimulation) (Table 2). For instance,
NRS scores of fatigue at baseline showed a mean ± SD of
74.4 ± 12.5 and at week 5 a mean ± SD of 69.1 ± 16.3
(n = 33; difference = 5.2; t = 3.0 and p = 0.005). By con-
trast, differences in fatigue NRS ratings between baseline
and week 5 were not significant in the “sham first” group
(n = 30; baseline fatigue NRS scores 74.7 ± 14.3 versus
week 5 scores 73.1 ± 15.0; difference = 1.6; t = 1.8 and
p = 0.087). The interaction, however, was not significant
(F = 3.4 and p = 0.068).
Secondary outcomes
The advantage of vibrotactile stimulation over sham was
also significant for restoring sleep quality. That is, the
changes observed for the “Unrefreshed Sleep” variable
generally paralleled the results of pain and fatigue
(Table 3). As for disorder impact, the effect of vibrotac-
tile stimulation had a non-significant tendency to be
higher (compared with sham) for both measures (Daily
Activity Impact and Fibromyalgia Impact Questionnaire)
. Vibrotactile stimulation had no significant effect on
emotional distress assessed on the Hospital Anxiety and
Depression Scale.
Additional “intent-to-treat” analysis
Although the aim of our study was to reflect actual
treatment differences, an additional analysis was carried
out including all patients with available outcome mea-
sures (n = 67). The results were almost identical for all
Table 1 Clinical characteristics (n = 63)
Age, years, mean (SD) 53.7 (8.1)
Sex, females, n (%) 63 (100)
Height, cm, mean (SD) 161 (6)
Weight, kg, mean (SD) 69.2 (13.6)
Hand-dominance, n (%) right-handers 56 (89)
Education level, years, mean (SD) 14.1 (3.9)
Illness duration, mean (SD), years since diagnosis 7.7 (5.8)
Fibromyalgia Impact Questionnaire*, mean (SD) 63.6 (15.1)
General perception of health**, mean (SD) 33.1 (17.6)
Hospital Anxiety and Depression Scale (HADS)
Anxiety, mean (SD) 11.2 (4.1)
Depression, mean (SD) 9.8 (4.4)
Stable medication regime
NSAIDs, n (%) 29 (46)
Opioids (tramadol), n (%) 24 (38)
Paracetamol, n (%) 34 (54)
Gabapentin, n (%) 25 (40)
Antidepressants
SSRI, n (%) 18 (29)
SNRI, n (%) 20 (32)
Others, n (%) 14 (22)
Anxiolytics/hypnotics (benzodiazepines), n (%) 42 (67)
*Fibromyalgia Impact Questionnaire (FIQ), maximum score, 100. **According
to the 36-Item Short-Form Health Survey, maximum score, 100. Several
patients were taking more than one medication. NSAIDs non-steroidal anti-
inflammatory drugs, SSRI selective serotonin reuptake inhibitor, SNRI serotonin-
norepinephrine reuptake inhibitor
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variables with the exception of Daily Activity Impact and
Fibromyalgia Impact Questionnaire. Differences between
vibrotactile stimulation and sham for Daily Activity Im-
pact rating in this analysis showed t = 2.1 and p = 0.041,
and Fibromyalgia Impact Questionnaire score t = 2.0 and
p = 0.049 (with data missing from one patient in the
Fibromyalgia Impact Questionnaire), both in the direc-
tion of symptom improvement being higher for vibrotac-
tile stimulation. It is noteworthy that, in the primary
analysis, both variables showed only a tendency to statis-
tical significance (Table 3).
Adverse effects
Both vibrotactile stimulation and sham were generally
well tolerated. 101-point NRS for discomfort showed a
mean ± SD of 11.9 ± 23.6 in patients receiving vibrotac-
tile stimulation and 6.1 ± 21.9 when receiving sham (n =
67; t = 1.7 and p = 0.099). Two additional patients were
Table 2 Fibromyalgia key symptoms
All patients (n = 63) Baseline (Bvs) Vibrotac. S. (VS) Baseline (Bsham) Sham (Bvs − VS) > (Bsham − Sham)
Pain 71.3 ± 13.1 54.4 ± 23.5 69.9 ± 15.1 62.5 ± 21.0 F = 6.5 p = 0.014
Fatigue 73.8 ± 13.7 53.1 ± 26.4 71.8 ± 15.5 64.3 ± 22.9 F = 12.0 p = 0.001
Cognitive symptoms 65.5 ± 18.1 62.0 ± 21.0 65.8 ± 18.2 64.1 ± 19.4 F = 1.6 p = 0.206
Vibrotactile S first (n = 33) Baseline (B1) Vibrotac. S. (VS) Baseline (B2) Sham (B1 − VS) > (B2 − Sham)
Pain 71.2 ± 10.4 48.0 ± 26.1 66.4 ± 16.3 62.8 ± 20.0 t = 4.0 p = 0.0003
Fatigue 74.4 ± 12.5 46.8 ± 27.8 69.1 ± 16.3 65.7 ± 21.9 t = 5.1 p = 0.00001
Cognitive symptoms 66.5 ± 18.0 61.9 ± 22.4 66.4 ± 18.1 63.9 ± 20.3 t = 0.9 p = 0.359
Sham first (n = 30) Baseline (B1) Sham Baseline (B2) Vibrotac. S. (VS) (B2 − VS) > (B1 − Sham)
Pain 73.7 ± 12.9 62.2 ± 22.4 71.3 ± 15.7 61.3 ± 18.3 t = − 0.3 p = 0.783
Fatigue 74.7 ± 14.3 62.7 ± 24.2 73.1 ± 15.0 60.1 ± 23.4 t = 0.2 p = 0.842
Cognitive symptoms 65.2 ± 18.6 64.4 ± 18.8 64.4 ± 18.5 62.1 ± 19.7 t = 0.9 p = 0.382
(B1 − VS) > (B1 − Sham) (B2 − VS) > (B2 − Sham)
Pain t = 2.2 p = 0.034 t = 1.5 p = 0.149
Fatigue t = 2.9 p = 0.005 t = 2.3 p = 0.025
Cognitive symptoms t = 1.9 p = 0.071 t = − 0.1 p = 0.911
Fig. 3 Bar graphs showing NRS score reduction for the three fibromyalgia key symptoms
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initially excluded due to excessive discomfort; one who
failed to tolerate vibrotactile stimulation and the other
failing to tolerate sham (Fig. 2). Six patients required the
intensity of the stimulus to be reduced to 66% of the
prescribed power due to discomfort; in 4 cases while be-
ing treated with vibrotactile stimulation and in 2 cases
with sham (χ2 = 0.5 and p = 0.674). Therefore, night-time
vibrotactile stimulation did not generally affect sleep in
patients, but it did significantly improve sleep quality in
the whole study group (Table 3).
Discussion
Vibrotactile stimulation was significantly superior to sham
in alleviating fibromyalgia symptoms globally. However,
univariate analyses showed that the effect was not universal.
Benefits were perceived on unpleasant somatic sensations
such as generalized pain and fatigue, but not on poor cog-
nition, anxiety, and depression. Vibrotactile stimulation was
notably well tolerated and sleep quality significantly im-
proved despite the vibrations being administered at night.
The extent of symptom improvement may be sufficiently
relevant to suggest a potential role for vibrotactile stimula-
tion as symptomatic treatment in fibromyalgia. Moreover,
the ease with which it can be administered during sleep,
with no other action required than turning on the system
at bed time, may eventually facilitate long-term compliance,
which is a relevant limiting factor for the success in treating
chronic disorders [35].
We have proposed that non-nociceptive somatosensory
stimulation, here administered in the form of extensive
and gentle mechanical vibrations, may favor the recovery
of sensory balance in fibromyalgia. Our empirical results
are indeed consistent with this hypothesis. However, the
effect of vibrotactile stimulation on the sensory system
has not been directly tested in this study. The evidence of
central nervous system sensory alteration has been ob-
tained from functional connectivity and task activation
MRI [5–10]. Further neuroimaging research is thus neces-
sary to specifically test the effects of vibrotactile stimula-
tion on the sensory balance. Nonetheless, it is important
Fig. 4 Bar graphs showing NRS score reduction for fatigue separately for each allocation group to illustrate the intervention order effect
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to emphasize that symptom improvement in our study
was perceived at day time with no vibrations and that their
effects persisted 2 weeks after the treatment was termi-
nated. The fact that the effects endured beyond stimula-
tion may well indicate some functional rearrangement as
opposed to a transient interference with pain signals at
the entry gate [36].
Symptoms in the fibromyalgia syndrome are not inde-
pendent clinical expressions but are highly interrelated.
For instance, chronic pain, as a stressful situation, may
favor fatigue and, conversely, fatigue may augment pain
perception. Moreover, unrefreshing sleep may potentiate
the feeling of both pain and fatigue. Sleep quality signifi-
cantly improved in our study (Table 3). Therefore, there
is a possibility that sleep improvement was to some ex-
tent a primary driver of the improved pain and fatigue.
In turn, a significant degree of pain relief may well con-
tribute to improving sleep quality. Future research may
interestingly be addressed to disentangle fibromyalgia
symptom interactions.
Important methodological aspects in our study in-
cluded the control of therapeutic effects with strict sham
and the rigorous observation of blind conditions. Our
study adopted the strategy of using the same device to ad-
minister both types of intervention, presented to patients as
two potentially effective options. The paraphernalia sur-
rounding the interventions, implicating the home installa-
tion of a motorized mattress controlled by a computerized
engine, was identical for both vibrotactile stimulation and
sham. The placebo effect in these circumstances was indeed
large and significant (e.g., first period fatigue reduction in
the group sham first showed t = 3.6 and p = 0.001). How-
ever, the placebo effect was virtually nonexistent when
sham was administered in the second period. This is rele-
vant in that it may indicate that the control of treatment ef-
fects with our sham approach was not complete in this
period, which is admittedly a limitation in our study. On
the other hand, the data may also inform on the magnitude
of placebo response and its dynamics in such an intricate
chronic pain disorder as fibromyalgia, and contributes to
current efforts to improve the characterization of pla-
cebo effects on pain [37, 38]. It is also noteworthy
that, in studies reporting the effect of nonpharmaco-
logical treatment for chronic pain, the most common
comparison has been against “usual care” with no
control of the placebo effect [17].
Table 3 Secondary outcome measures
All patients (n = 63) Baseline (Bvs) Vibrotac. S. (VS) Baseline (Bsham) Sham (Bvs − VS) > (Bsham − Sham)
Unrefreshed Sleep 69.6 ± 17.8 55.1 ± 22.5 67.1 ± 18.5 60.3 ± 23.4 t = 2.2 p = 0.033
Daily Activity Impact 70.6 ± 17.9 67.9 ± 16.9 69.7 ± 17.8 69.8 ± 18.6 t = 1.7 p = 0.098
Anxiety (HADS) 10.9 ± 4.4 10.1 ± 3.9 11.0 ± 3.9 10.9 ± 4.3 t = 1.4 p = 0.164
Depression (HADS) 9.3 ± 4.7 9.3 ± 4.7 9.3 ± 4.4 9.3 ± 4.6 t = − 0.6 p = 0.955
FIQ 61.9 ± 16.2 54.8 ± 17.3 60.7 ± 17.9 58.1 ± 18.0 t = 1.9 p = 0.069
Vibrotactile S. first (n = 33) Baseline (B1) Vibrotac. S. (VS) Baseline (B2) Sham (B1 − VS) > (B2 − Sham)
Unrefreshed Sleep 70.8 ± 16.8 52.7 ± 23.8 61.9 ± 20.6 61.9 ± 24.2 t = 4.4 p = 0.0001
Daily Activity Impact 68.9 ± 19.4 64.8 ± 18.6 66.6 ± 19.0 67.7 ± 20.3 t = 2.4 p = 0.020
Anxiety (HADS) 10.7 ± 4.7 10.0 ± 3.8 10.5 ± 4.2 10.7 ± 4.4 t = 1.1 p = 0.261
Depression (HADS) 9.8 ± 4.8 9.4 ± 4.5 9.0 ± 4.8 9.6 ± 4.7 t = 1.5 p = 0.148
FIQ 63.1 ± 14.0 54.1 ± 18.2 57.5 ± 19.0 58.3 ± 18.7 t = 3.4 p = 0.002
Sham first (n = 30) Baseline (B1) Sham Baseline (B2) Vibrotac. S. (VS) (B2 − VS) > (B1 − Sham)
Unrefreshed Sleep 72.8 ± 14.1 58.6 ± 22.7 68.4 ± 19.1 57.6 ± 21.0 t = − 0.6 p = 0.527
Daily Activity Impact 73.2 ± 15.9 71.1 ± 16.7 72.4 ± 16.2 71.3 ± 14.3 t = − 0.7 p = 0.502
Anxiety (HADS) 11.6 ± 3.4 11.2 ± 4.2 11.2 ± 4.2 10.2 ± 4.0 t = 0.8 p = 0.427
Depression (HADS) 9.8 ± 3.9 8.9 ± 4.6 8.8 ± 4.6 9.1 ± 4.9 t = − 1.4 p = 0.171
FIQ 64.2 ± 16.3 57.8 ± 17.5 60.7 ± 18.4 55.6 ± 16.5 t = − 0.4 p = 0.753
(B1 − VS) > (B1 − Sham) (B2 − VS) > (B2 − Sham)
Unrefreshed Sleep t = 1.0 p = 0.336 t = 2.2 p = 0.029
Daily Activity Impact t = 1.4 p = 0.162 t = 1.3 p = 0.198
Anxiety (HADS) t = 0.3 p = 0.759 t = 1.8 p = 0.082
Depression (HADS) t = −0.6 p = 0.549 t = 0.5 p = 0.595
FIQ t = 0.7 p = 0.462 t = 1.6 p = 0.111
FIQ Fibromyalgia Impact Questionnaire, HADS Hospital Anxiety and Depression Scale
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A limitation in our study, however, precisely concerns
the carryover effects. Although a complete counterbalan-
cing in our study prevents inflation effects of either
treatment option, carryover did significantly influence
the magnitude of change during the second period in
two ways. Firstly, symptom change was attenuated in the
second period, with the previously described lack of sig-
nificant placebo effects, and, secondly, the effect of
vibrotactile stimulation persisted at least until week 5.
Although this would interestingly suggest that the effect
of vibrotactile stimulation in fibromyalgia is long-lasting,
washout time should be better adjusted in future studies.
Another study limitation involves to the general prob-
lems inherent to subjective symptom measurements. It
is very difficult for people, particularly for patients with
chronic pain, to reliably rate the amount of perceived
pain, or feelings in general [28, 29, 39]. We opted to as-
sess outcome measures at the end of the study to facili-
tate the comparison of treatment effects using baseline
scores as reference.
Conclusions
The effect of gentle vibrotactile stimulation of the body
on symptom relief was tested in the framework of a con-
trolled clinical trial in fibromyalgia patients. Results
showed significant reduction of pain and fatigue, and
sleep quality improved despite the fact that stimulation
was applied during sleep time. The degree of improve-
ment and the easy application of our proposal would
seem to be sufficiently relevant to suggest a potential
role for vibrotactile stimulation in the treatment of
fibromyalgia symptoms.
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